Future Fields, a Edmonton, Canada-based fly biotechnology company, raised $11.2M USD in funding.
The round was led by Bee Partners and Toyota Ventures with participation form Builders VC, AgFunder, Amplify Capital, Milad Alucozai of BoxOne Ventures, Green Circle Foodtech, Siddhi Capital and Climate Capital.
The company intends to use the funds to hire key personnel and build out its first production facility, which will enable the production of recombinant proteins at kilogram scale—with just 10,000 square feet of manufacturing space. The facility will be located right beside its corporate headquarters in Edmonton, Canada and produce proteins for cell culture with a smaller greenhouse gas footprint than existing bioreactor technology.
Co-founded by Matt Anderson-Baron (CEO) and Jalene Anderson-Baron (COO), Future Fields is a fly biotechnology company. Its biomanufacturing platform, the EntoEngine, is a synthetic biology system that uses fruit flies for recombinant protein production.
Founded first to transform the creation of cultivated beef, chicken and fish, Future Fields is adding a new suite of human recombinant protein products created by its patented EntoEngine™ which target medical research and biopharmaceuticals. Altogether, these include:
- PDGF-bb: a clinically approved protein for wound healing and bone graft additive
- Activin A: an important hormone in reproductive biology and which not only impacts fertility treatments but also islet cells for transplantation
- IGF-1: a hormone that spurs muscle development and maintenance
- Prolactin: a hormone responsible for breast milk development
- FGF2: a key component of stem cell research with applications in traumatic spinal cord injury, stroke, severe burns and more